Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease

Natalia Salvadores1,2,9, Ines Moreno-Gonzalez3,4,5, Nazaret Gamez3,5, Gabriel Quiroz2, Laura Vegas-Gomez3, Marcela Escandón1, Sebastian Jimenez4,6,7, Javier Vitorica4,6,7, Antonia Gutierrez3,4, Claudio Soto5 and Felipe A. Court1,2,8*

Abstract

Alzheimer’s disease (AD) is a major adult-onset neurodegenerative condition with no available treatment. Compelling reports point amyloid-β (Aβ) as the main etiologic agent that triggers AD. Although there is extensive evidence of detrimental crosstalk between Aβ and microglia that contributes to neuroinflammation in AD, the exact mechanism leading to neuron death remains unknown. Using postmortem human AD brain tissue, we show that Aβ pathology is associated with the necroptosis effector pMLKL. Moreover, we found that the burden of Aβ oligomers (Aβo) correlates with the expression of key markers of necroptosis activation. Additionally, inhibition of necroptosis by pharmacological or genetic means, reduce neurodegeneration and memory impairment triggered by Aβo in mice. Since microglial activation is emerging as a central driver for AD pathogenesis, we then tested the contribution of microglia to the mechanism of Aβo-mediated necroptosis activation in neurons. Using an in vitro model, we show that conditioned medium from Aβo-stimulated microglia elicited necroptosis in neurons through activation of TNF-α signaling, triggering extensive neurodegeneration. Notably, necroptosis inhibition provided significant neuronal protection. Together, these findings suggest that Aβo-mediated microglia stimulation in AD contributes to necroptosis activation in neurons and neurodegeneration. As necroptosis is a druggable degenerative mechanism, our findings might have important therapeutic implications to prevent the progression of AD.

Keywords: Alzheimer’s disease, Amyloid-β oligomers, Necroptosis, Microglia, Neurodegeneration, Neuroprotection
role to Aβ in the etiopathogenesis of AD [2, 8]. Neuroinflammation is a critical component of the pathogenesis of Aβ, involving abnormal activation of glial cells and the production of various proinflammatory cytokines [9]. Following the first description of activated microglial cells in close contact with amyloid plaques in AD brains, extensive research focusing on the role of microglia in AD pathogenesis has been conducted [10–14]. Upon interaction with Aβ, activated microglia initiate an innate immune response that leads to sustained production and secretion of pro-inflammatory mediators including interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α), contributing to neuronal damage and cognitive decline [15–19]. Interestingly, mutations in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), which is expressed in microglia, increase the risk of AD by about 3- to 5-fold [20, 21]. TREM2 is involved in microglial signaling and plays an important role in Aβ phagocytosis as well as suppressing cytokine production and neuroinflammation [22–24]. These studies support an important contribution of inflammatory responses in the mechanism of Aβ-induced neurodegeneration.

Necroptosis is a mechanism of programmed cell death that participates in the pathogenesis of several diseases [25]. Necroptosis is activated in postmortem human AD brains and the expression of necrotic markers correlates with the disease stage and progression at the cognitive level [26, 27]. Nevertheless, the mechanism that triggers necroptosis in AD remains to be established. Different stimuli induce necroptosis activation, including TNF ligand family members [28], interferons [29], and toll-like receptor 3 stimulation [30]. Stimulation of TNF type 1 receptor (TNFR1) leads to the recruitment of receptor-interacting protein kinase 1 (RIPK1) [31, 32], which triggers the activation of either caspase-8 or RIPK3, leading to apoptosis or necroptosis, respectively [33]. Following a stimulus such as TNF-α ligation, and in the absence of caspase-8 activity, the interaction of RIPK1 and RIPK3 induces the formation of the necroosome complex and RIPK3 phosphorylation, a key event in necroptosis activation [34–36]. RIPK3 activation leads to the recruitment and phosphorylation of the pseudokinase mixed lineage kinase domain-like protein (MLKL) within the necroosome complex. Upon activation, MLKL is oligomerized and executes necroptosis leading to cell death [37, 38]. Interestingly, recent studies suggest that necroptosis may operate as a relevant degenerative pathway in models of amyotrophic lateral sclerosis (ALS) [39], multiple sclerosis (MS) [40], and Parkinson’s disease (PD) [41].

Here, we investigated the role of Aβ pathology in the mechanism underlying necroptosis activation in AD. We found that Aβ oligomers (Aβo) are associated with key necroptosis drivers in the brains of AD patients and that targeting this death mechanism reduces Aβo-related neurodegeneration and memory impairment in mice. Furthermore, we report that in vitro, Aβo elicit necroptosis-mediated neurodegeneration via microglia activation through the engagement of TNF-α signaling. This study sheds light on the role of necroptosis in the crosstalk between glial and neuronal cells in AD and provides evidence indicating that necroptosis constitutes a potential therapeutic target for the disease.

Methods

Human samples

Histological analyses: Hippocampal brain samples were obtained from the Neurological Tissue Bank of IDIBELL-Hospital of Bellvitge (Barcelona, Spain) fixed in formaldehyde and embedded in paraffin. Research on human samples was performed following the code of ethics of the World Medical Association (Declaration of Helsinki). Samples were manipulated following the universal precautions for working with human samples and as directed by the supplier biobank and local ethics committees following Spanish legislation.

Molecular and biochemical analyses: autopsy specimens from the medial temporal lobe (hippocampal/parahippocampal regions) were obtained from the tissue bank Fundación CIEN (BT-CIEN; Centro de Investigación de Enfermedades Neurologicas; Madrid, Spain) and from the Neurological Tissue Bank of IDIBELL-Hospital of Bellvitge (Barcelona, Spain). The utilization of postmortem human samples was approved by the corresponding biobank ethics committees and by the “Comité de Ética de la Investigacion (CEI), Hospital Virgen del Rocio”, Seville, Spain. We considered the age-matched Braak II individuals as controls in our experiments. Only Braak V–VI cases were clinically classified as demented (AD) patients.

Mice

MLKL knockout mice were kindly provided by Dr. Douglas Green (St. Jude Children’s Research Hospital, Memphis, TN, USA) and have been described previously [42]; male (4–6 months old) mice were used, wild-type littermates were used as controls. For the GSK872 experiment, C57BL/6 mice were used and were obtained from Jackson Laboratory (Bar Harbor, ME, USA), male (13–14 months old) mice were used. Animals were housed in groups of a maximum of five in individually ventilated cages under standard conditions (22 °C, 12 h light–dark cycle) receiving food and water ad libitum. All animal manipulations were carried out in accordance with standard regulations and approved by the Animal...
Intracerebroventricular injection
Mice were anesthetized with isoflurane and placed in a stereotaxic frame (David Kopf Instruments, USA). A single cerebroventricular injection was performed in both lateral ventricles according to the following stereotaxic coordinates: −1.0 ± 0.06 mm posterior to bregma, 1.8 ± 0.1 mm lateral to the sagittal suture, and 2.4 mm in depth, as previously described [43]. Five μl of a solution of Aβo (100 μM) or vehicle (PBS) were injected in each ventricle at a rate of 0.5 μl/min. Behavioural and histopathological analysis were performed at 14 and 18 days after the injection, respectively.

GSK’872 administration
GSK’872 (Tocris Bioscience) was dissolved in DMSO to a final concentration of 100 mM (stock). The working solution was prepared by diluting the stock solution with DMSO and then sterile PBS at room temperature to 0.3 mM (20% DMSO). The vehicle consisted of a solution of 20% DMSO in PBS. GSK’872 or vehicle were administered via intraperitoneal injection (1 mg/Kg) at the day of the intracerebroventricular injection of Aβo (day 0), and then at day 7 and 14 post-injection.

Behavioral assessment
Two weeks after surgery (day 14), cognitive performance was tested using the Morris Water Maze as previously described [44]. In this test, using visual cues for orientation, animals learn to swim to a hidden platform under the water. During the training, mice are placed into the water. During the training, mice are placed into the pool and allowed to explore for 1 min. If the animals do not find the platform, they are guided to it. This training procedure was performed 4 times a day for four consecutive days per animal. On day five, the platform was removed from the pool, and the time that the animals spent in the target quadrant was measured. At the end of the experiments, animals were euthanized by an overdose of anesthesia, and all efforts were made to minimize suffering. Then, animals were transcardially perfused with 50 mL of PBS.

Preparation of synthetic oligomers
Aβo were prepared as previously described [45]. Briefly, lyophilized recombinant Aβ42 peptide (rPeptide, A-1163) was re-suspended to 5 mM in DMSO and then further diluted to 100 μM in cold Neurobasal medium for the in vitro experiments or in sterile PBS for the in vivo experiments. The peptide was incubated at 4 °C for 24 h to generate oligomers, which were characterized by electron microscopy.

Total RNA extraction, retrotranscription, and quantitative real-time PCR
Total RNA was extracted from human samples using TriPure Isolation Reagent (Roche). RNA integrity (RIN) was determined by RNA Nano 6000 (Agilent). No differences between the Braak groups were observed (RIN: 6.95 ± 1.4). RNA was quantified using NanoDrop 2000 spectrophotometer (Thermo Fischer). Retrotranscription (RT) (4 μg of total RNA) was performed with the High-Capacity cDNA Archive Kit (Applied Biosystems). For quantitative real-time PCR (qPCR), 40 ng of cDNA were mixed with 2 × Taqman Universal Master Mix (Applied Biosystems) and 20 × Taqman Gene Expression assay probes (Ripk1, Hs01041869_m1; Ripk3, Hs00179132_m1; Mlkl, Hs04188505_m1; Applied Biosystems). qPCR reactions were done using an ABI Prism 7900HT (Applied Biosystems). The cDNA levels were determined using GAPDH and beta-actin. We observed a highly significant linear correlation between the cycle threshold (Ct) of both genes (beta-actin vs GAPDH, r = 0.912, F[1, 46] = 157.73, p < 0.0001). Thus, normalization using either beta-actin (Hs99999903_1, Applied Biosystems) or GAPDH (Hs03929097_g1, Applied Biosystems) produced identical results. Routinely, we used GAPDH as housekeeper. Results were expressed using the comparative double-delta Ct method (2−ΔΔCt). ΔCt values represent GAPDH normalized expression levels. ΔΔCt was calculated using Braak II.

Preparation of soluble S1 fractions
Soluble S1 fractions from human samples were prepared as described [46]. Briefly, human tissue was homogenized (Dounce homogenizer) in TBS (20 mM Tris–HCl, 140 mM NaCl, pH 7.5) containing protease and phosphatase inhibitors (Roche). Homogenates were ultracentrifuged (4 °C for 60 min) at 100,000 × g (Optima MAX Preparative Ultracentrifuge, Beckman Coulter). Supernatants (S1 fractions), were aliquoted and stored at −80 °C.

Tissue processing for histopathology
For the study of human samples, deparaffinized 10-μm-thick sections were used. After auto-fluorescence blocking (Millipore), sections were subjected to antigen retrieval by heating at 80 °C for 30 min in 10 mM citrate buffer pH 6.0. Samples were blocked with 5% BSA diluted in PBS Tx-100 (0.2%). For double staining, samples were incubated with anti-pMLKL (1:200, Sabbitech) for 48 h and stained with...
Thioflavin-S (0.025% in PBS) for 8 min. Signal was detected incubating for 1.5 h with the corresponding Alexa secondary antibody (1:500, Invitrogen). For double immunostaining with anti-pMLKL (1:200, Sabbiootech) and anti-MAP2 (1:5000, Thermo Fisher) or anti-Iba-1 antibodies (1:1000, Wako), samples were incubated overnight at 4 °C. Then, sections were incubated with the corresponding Alexa secondary antibodies (1:1000). For triple staining, samples were incubated for 10 min in Amylo-Glo® RTD (Biosensis), washed, and consecutively incubated with anti-pMLKL and anti-Iba-1 antibodies. Signal was detected as described above. Finally, samples were treated with an antifade mounting medium (VECTASHIELD). Fluorescent microscopy images were taken in a Leica SP8 confocal laser microscope coupled to a computer with TCS NT software (Leica).

For the histological study on mice, following perfusion, the whole brain was quickly removed, the right hemisphere was fixed with 4% PFA and then incubated in 30% sucrose before for OCT-embedding. Brains were sagittally cut into 20-μm-thick serial slices using a cryostat. Tissue sections were rinsed with TBS and then mounted onto superfrost plus slides. Antigen retrieval was performed by submerging slices in 10 mM citrate buffer pH 6.0 at 100 °C for 20 min. Samples were blocked with 5% BSA and then incubated with the antibody solution (anti-pMLKL 1:200, Abcam; anti-Iba1 1:700, Wako), overnight at 4 °C. Finally, antigens were visualized by incubating with the corresponding Alexa secondary antibodies (1:500, Thermo Fisher). Fluoro-Jade C staining: the FJC ready-to-dilute staining kit (Biosensis) was used. Briefly, sections were immersed in a basic alcohol solution consisting of 1% sodium hydroxide in 80% ethanol for 5 min, followed by 2 min in 70% ethanol and 2 min in distilled water. Then, sections were incubated for 10 min in a solution of 0.06% potassium permanganate. Samples were rinsed in distilled water and stained for 10 min with the FJC solution. After rinsing, the air-dried slides were cleared in xylene for 1 min and then coverslipped. Images were obtained using a Leica DMi8 microscope.

**Image analysis**

All analyzes were carried out using Image J software (v1.42q). Colocalization analysis: The Coloc2 plugin was used to calculate the Manders Correlation values for intensities above Costes threshold. These values were used to obtain the ratio of pixels from one channel that colocalizes with total pixels in the second channel. The percentage of stained area was determined in thresholded images, by quantifying the signal above threshold divided by the total image area. Total stained area in a specific ROI was determined in thresholded images, by quantifying the signal above threshold in that ROI divided by the area of the ROI.

**Cell culture**

**Hippocampal neuronal cultures:** Primary neuronal cultures were prepared from embryonic Sprague–Dawley rats (E18). Briefly, meninges-free hippocampi were isolated, trypsinized, and plated onto poly-L-lysine (0.05 mg/ml)-coated glass coverslips on tissue culture wells (150 cells/mm²). Neurons were grown in Neurobasal media with L-glutamine and B27 supplements to consistently provide neuronal cultures > 95% pure. Cultures were treated with 1 µM AraC to inhibit glial cell proliferation. For all experiments, neurons were treated on in vitro day 7.

**Microglial cell culture:** Microglial cells were cultured from postnatal day 3 Sprague–Dawley rat brains. Briefly, meninges-free cortices were dissected, and cells were mechanically dissociated. Cells were plated onto tissue culture flasks in DMEM media containing 10% heat-inactivated fetal bovine serum. Culture medium was replaced on in vitro days 1 and 5. After 10 days, the cultures were shaken for 2 h at 180 rpm on a rotary shaker to remove microglia.

**Co-cultures:** Hippocampal and microglial cell cultures were performed as described above. Microglial cells were added to hippocampal neuronal cultures at a ratio of 1:1, at in vitro day 7, 4 h before Aβo treatments.

**Preparation of conditioned medium**

Conditioned medium was prepared as previously described [47]. Microglial cells (180 cells/mm²) were plated onto immobilized Aβo (7.3 pmol/mm²) to prevent their subsequent collection in the conditioned medium. To immobilize the oligomers, tissue culture dishes were coated with nitrocellulose that was obtained by dissolving a piece of membrane in methanol. Oligomers were distributed on the dish and allowed to dry for 10 min. Then, the dish was washed twice and blocked with 5% BCA in DMEM. After 48 h of stimulation, the microglial conditioned medium was collected and stored at −80 °C. To prepare the control medium, the same process was performed except that oligomers were not added. Additionally, a negative control was prepared by collecting medium from dishes containing immobilized Aβo alone.

**Immunofluorescence**

Neurons were fixed in 4% PFA at room temperature for 20 min. Cells were then blocked using 5% fish gelatin,
0.1% triton-X-100 for 2 h. Then, cells were incubated with the primary antibody solution (anti-acetylated tubulin 1:1000, Sigma-Aldrich; anti-Iba1 1:4000, Wako) overnight at 4 °C. After washing with PBS, cells were incubated with the secondary antibody solution (goat anti-mouse alexa 488 or 546 1:500, Thermo Fisher) for 1 h at room temperature. Cells were washed and cover-slipped with Mowiol mounting medium (Sigma).

**Protein extraction, quantification, and co-immunoprecipitation**

Briefly, cells were collected with a cell scraper and centrifuged at 5000 × g for 5 min. The pellet was re-suspended in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 μg/ml PMSF) with phosphatase and protease inhibitor cocktail and stored at −80 °C. Protein levels were quantified with Pierce BCA Protein Assay Kit (Thermo Scientific). Immunoprecipitation experiments were performed by incubating 100 μg of protein with 2.5 μg of anti-RIPK1 (BD Transduction Laboratories) with rotation at 4 °C for 48 h. Then, 50 μl of protein G magnetic beads (Biorad) were added to each sample and incubated with rotation at 4 °C for 3 h. Following magnetic separation, beads were mixed with loading buffer and boiled at 90 °C for 5 min. After the elution step, samples were analyzed by western blotting as described.

**Western blot**

Proteins were fractionated by electrophoresis using 10% sodium dodecyl sulphate (SDS) polyacrylamide gels, electroblotted into PVDF membranes (Hybond-P, GE Healthcare), and blocked with 5% BCA in TBS. Membranes were then incubated with the different antibodies (anti-RIPK3, abcam ab16090; anti-pMLKL, abcam ab196436; and anti-HSP90, Santa Cruz sc7947) overnight at 4 °C, followed by incubation with a horseradish peroxidase-conjugated antibody. The immunoreactive bands were visualized using ECL (Invitrogen). The images were obtained and analyzed with ChemiDoc™ Touch Imaging System (Bio-Rad). For the immunoprecipitation experiments, detection of the IgG was done following the detection of pMLKL, using membranes that were stripped with a solution containing glycine 0.2 M, SDS 0.1%, Tween 20 0.1%, pH 2.2 (2 × 5 min incubation). After confirming that no bands could be visualized with ECL, membranes were blocked and incubated with a horseradish peroxidase-conjugated anti-mouse antibody. To analyze Aβ in human samples, protein samples were loaded onto 16% SDS-Tris-Tricine-PAGE and transferred to PVDF (Immobilon-P, Millipore). After blocking, using 5% non-fat milk, the membranes were incubated overnight, at 4°C, with a mixture of N-terminus (clone 82E1) mouse monoclonal (1:1000, IBL) and anti-Aβ (clone 6E10) mouse monoclonal (1:1000, Signet).

**Dot blot**

Dot blots were done as described previously [48]. Briefly, 1 μg of protein from the different S1 fractions was first treated with PureProteome Protein G Magnetics Beads (Millipore) for contaminant IgG depletion and then directly applied to dry nitrocellulose, in a final volume of 2 μl. Then, blots were blocked for 1 h and incubated overnight at 4 °C with anti-Amyloid fibrils (OC, 1:5000, Merck-Millipore), anti-prefibrillar oligomers (A11, 1:5000 Invitrogen), anti pMLKL (1:1000, abcam) or anti-GAPDH (1:10,000, Cell Signalling) antibodies. Blots were visualized using the Pierce ECL 2 Western Blotting Substrate detection method (0.5 pg, lower limit sensitivity; Thermo Scientific). The images were obtained and analyzed with ChemiDoc™ Touch Imaging System (Bio-Rad). Data were always normalized by the specific signal observed in the Braak II group.

**Statistical analyses**

All experiments were analyzed in a blinded manner. To analyze differences in the data obtained from molecular and biochemical analyses of human samples, data were compared by Kruskal-Wallis test followed by Dunn post hoc test. For the association analyses, linear regression was done using the Spearman rho-test. Data from all other studies were statistically analyzed using Student’s t-test (for two groups comparisons) or one-way ANOVA (for more than two groups) followed by Bonferroni’s post hoc test. For the association analyses, linear regression was done using Pearson correlation. Data are shown as mean ± SEM. All analyses were performed using Graph Pad Prism 5.0 software. Differences were considered significant with p < 0.05.

**Results**

Aβ pathology is associated with necroptosis activation in human AD brains

Although evidence for necroptosis activation has been reported in the brain of patients with AD [26, 27], the possible association between Aβ pathology and necroptosis activation has not been established. Therefore, we studied the association between Aβ and phosphorylated MLKL at Ser358 (pMLKL), which defines the activation of a canonical necrototic process, in brain samples derived from the hippocampus of sporadic AD, mild cognitive impairment (MCI), and control (CTRL) cases (clinical data of the subjects used in the histopathological study are listed in Table 1). The histopathological assessment revealed low pMLKL immunoreactivity in the hippocampus of control samples (Fig. 1A). Of the four
whether pMLKL immunoreactivity localizes to neurons or microglia in AD. To this aim, we conducted colocalization analyses between pMLKL and MAP2 or Iba1, respectively, using AD brain tissue (Fig. 1D, E). The results revealed that most of the pMLKL immunoreactivity colocalized with MAP2. This result suggests that necroptosis activation occurs mainly in neurons of the AD brain.

Several lines of investigation indicate that Aβ oligomers (Aβo) contribute importantly to neurodegeneration in AD [2, 3]. Indeed, previous studies have demonstrated that soluble oligomeric Aβ correlates better with cognitive deficits compared to plaques, which can actually sequester oligomers, acting as reservoirs from which oligomers can diffuse, reaching cellular targets in their vicinity [4–7]. Thus, we next moved forward to determine the relationship between the burden of Aβo and necroptosis activation in AD brains. To this end, we evaluated the association between Ripk1, Ripk3, and Mlkl mRNA levels and the levels of soluble Aβo in postmortem brain samples of AD patients at different stages of the disease (clinical data of the subjects used in this study are summarized in Table 2). Samples were divided into three groups: samples derived from Braak II, non-demented individuals, which did not accumulate Aβ in the hippocampus; samples from Braak III-IV patients, which presented Aβ accumulation; and samples from Braak V-VI patients, which presented significantly higher levels of Aβ compared to the latter group (Fig. 2A, B). In agreement with previously reported data [26], we observed that the expression levels of Ripk1 and Mlkl, but not those of Ripk3, are elevated in the brains of individuals with higher Braak stages (Fig. 2C). The levels of oligomeric Aβ aggregates were assessed by dot blot using OC and A11 antibodies to detect soluble fibrillar and prefibrillar Aβo, respectively (Fig. 2D). The dynamic range and the coefficient of variation of the dot-blot assays are shown in Additional file 2: Fig. S2. Quantitative analysis revealed that the extent of both types of structures was significantly higher in the brains of AD patients compared to healthy controls (Fig. 2E). We found a significant and positive correlation between Aβo load and the levels of Ripk1 but not Ripk3 or Mlkl mRNA (Fig. 2F, G). Since MLKL activation is post-translationally regulated by phosphorylation, we then measured the association of pMLKL levels with the load of Aβo in AD brain samples. To achieve this, pMLKL levels were determined by dot blot (Fig. 2H). Quantitative measurement showed significantly increased pMLKL levels in AD subjects compared to controls (Fig. 2I). Notably, the levels of pMLKL correlate significantly and positively with the burden of Aβo (Fig. 2J, K). These results suggest a link between oligomeric Aβ structures and activation of the necroptotic machinery.

| Condition | Gender | Age | Braak stage | MMSE |
|-----------|--------|-----|-------------|------|
| CTRL M    | 80     | I   | 30          |      |
| CTRL F    | >89    | II  | 30          |      |
| CTRL N/A  | N/A    | II  | N/A         |      |
| MCI N/A   | N/A    | N/A | N/A         |      |
| MCI N/A   | N/A    | N/A | N/A         |      |
| MCI N/A   | N/A    | N/A | N/A         |      |
| AD M      | 65     | III | N/A         |      |
| AD M      | 84     | III | N/A         |      |
| AD F      | 79     | IV  | N/A         |      |
| AD M      | 75     | VI  | 0           |      |
| AD F      | 76     | VI  | 1           |      |
| AD F      | >89    | VI  | 6           |      |
| AD M      | 84     | VI  | N/A         |      |
| AD M      | 81     | VI  | N/A         |      |
| AD F      | 56     | VI  | N/A         |      |
| AD F      | 66     | VI  | N/A         |      |
| AD F      | 76     | VI  | N/A         |      |
| AD F      | 86     | VI  | N/A         |      |

CTRL control, MCI mild cognitive impairment, AD Alzheimer’s disease, M male, F female, N/A not available, MMSE mini-mental state examination
Together, these data provide the first evidence that Aβ pathology is associated with necroptosis activation in AD.

Targeting necroptosis ameliorates neurodegeneration and memory impairment induced by Aβo in mice

Given the role of Aβ aggregates as major pathological mediators of both familial and sporadic AD and considering that Aβo are generally regarded as the most pathogenic form of Aβ, animal models based on intracerebral Aβo inoculation have been established as useful tools to
study AD pathogenesis [3]. To assess whether Aβo can induce activation of the necroptosis pathway, we conducted an acute intracerebroventricular injection of synthetic Aβo to wild-type mice. As expected, Aβo injection triggered significant microgliosis compared to control mice (Fig. 3A, B). Moreover, Aβo treated mice underwent neurodegeneration in the hippocampus, as demonstrated by an increase in non-phosphorylated neurofilaments (Fig. 3C, D). Staining for pMLKL demonstrated significant necroptosis activation in Aβo injected mice compared to vehicle-injected ones (Fig. 3E,F). To validate the phospho-specific MLKL antibody, we compared the immunoreactivity of brain sections from wild-type and MLKL knock-out mice, treated with Aβo (Additional file 3: Fig. S3 A, B). In addition, to assess the cell specificity of the pMLKL immunostaining, we performed double labeling using antibodies to pMLKL and MAP2 or CD11b to observe neurons and microglia, respectively. As shown in Additional file 3: Fig. S3 C, D, most of the pMLKL signal observed in the hippocampus was associated with neurons. Notably, pMLKL expression positively correlated with neurodegeneration determined by Fluoro-Jade C staining (Additional file 4: Fig. S4) and negatively correlated with cognitive performance evaluated using the Morris water maze (MWM) behavioral test (Fig. 3G, H).

To evaluate the potential protective effect of MLKL inhibition against Aβo-induced neurodegeneration and memory alterations, we used genetically modified mice lacking Mlkl. To test the effects of targeting MLKL in the progression of AD pathogenesis, we evaluated neurodegeneration in the brain of these mice by histopathological assessment using Fluoro-Jade C staining. As shown in Fig. 3I,J, Aβo administration elicited significant neurodegeneration compared to control mice, evidenced by increased Fluoro-Jade C stained area in the hippocampus. Notably, ablation of Mlkl expression decreased the levels of Aβo-related neurodegeneration. To determine whether targeting MLKL influences the microgliosis observed following Aβo treatments, immunostaining was done using Iba1. Although similar levels of microglial activation were observed following Aβo infusion in transgenic and wild-type mice, no statistically significant differences were found between vehicle and Aβo-treated mice in the knock-out group (Additional file 5: Fig. S5).

In order to study the possible consequences of eliminating MLKL on the behavioral impairment observed in this AD model, we evaluated the memory capacity of mice using the MWM test. In agreement with previous reports [53, 54] Aβo-injected mice exhibited altered memory performance in the MWM test, as this group of animals spent less time in the target quadrant compared to control mice (Fig. 3K). In sharp contrast, Mlkl deletion significantly inhibited cognitive alterations observed in this AD model as the time spent in the target quadrant by MLKL−/− mice treated with Aβo was significantly longer compared to MLKL+/+ mice injected with the oligomers (Fig. 3K). The protection provided by Mlkl deletion was also reflected when measuring the distance that mice traveled in the target quadrant during the test (Fig. 3L). The time that mice spent in the target quadrant during the test is graphically represented in the heat map (Fig. 3M). Importantly, swim speed and total traveled distance were not modified by Aβo treatment (Fig. 3N, O), suggesting this model does not cause locomotor or visual impairment.

To increase the translational potential of these findings, we next investigated the possible protective effect of targeting necroptosis by pharmacological inhibition in this AD model. To this end, we treated mice with the RIPK3 inhibitor GSK872. Histopathological exploration of brain

### Table 2 Demographics of the individuals investigated by molecular and biochemical analyses of postmortem brain tissue

| Braak stage | Gender (male, %) | Gender (female, %) | Age (Years, mean ± SD) | Postmortem delay (mean ± SD) |
|-------------|-----------------|--------------------|------------------------|-------------------------------|
| II (n = 10) | 61.54           | 38.46              | 78 ± 8.5               | 7 ± 4                         |
| III–IV (n = 9) | 44.44          | 55.56              | 80 ± 11                | 6 ± 5                         |
| V–VI (n = 10) | 38.89          | 61.11              | 79 ± 10                | 8 ± 4                         |

(See figure on next page.)

**Fig. 2** Activation of RIPK1 and MLKL correlate with soluble Aβ oligomer burden in AD brains. **A** Western blot analysis of total protein extracts from hippocampal samples using a mix of 6E10 and 82E1 antibodies was performed to determine the Aβ content. **B** The specific band was quantified by densitometric analysis, and represented in the graphs. **C** The graph represents the expression levels of Ripk1, Ripk3, and Mlkl in human brain samples from patients at different AD stages (Braak stage II (n = 10), III–IV (n = 9), V–VI (n = 10)). **D** Dot blots of soluble proteins extracted from postmortem brains of individuals with Braak II (n = 4), Braak III–IV (n = 5), and Braak V–VI (n = 8), probed with the indicated antibodies. **E** Blots were quantified by densitometric analysis and expressed relative to GAPDH protein, represented in the graph. **F, G** Association analyses of oligomeric Aβ load and mRNA levels were done by linear regression. **H** Dot blots of protein extracts from postmortem brains of individuals with Braak II (n = 4), Braak III–IV (n = 5), and Braak V–VI (n = 8), probed with the indicated antibodies. **I** Blots were quantified by densitometric analysis and expressed relative to GAPDH protein, represented in the graph. **J, K** Association analyses of oligomeric Aβ load and pMLKL levels were done by linear regression. Data are presented as mean ± S.E.M. Data in **B, C, E, and I** were analyzed by Kruskal–Wallis test followed by Dunn post-hoc test. Data in **F, G, J, and K** were analyzed by linear regression using Spearman rho-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 2  (See legend on previous page.)
pMLKL levels revealed that intraperitoneal administration of GSK’872 significantly decreased necroptosis activation induced by Aβo (Fig. 4A, B). Moreover, evaluation of neurodegeneration using Fluoro-Jade C showed that GSK’872 significantly attenuated Aβo-related neurodegeneration to levels comparable to those detected in control mice (Fig. 4C,D). To determine whether targeting RIPK3 influences the microgliosis triggered by Aβo treatment, immunostaining was done using Iba1. As shown in Additional file 6: Fig. S6, Ripk3 ablation did not alter the microglial activation induced by Aβo, suggesting neuronal necroptosis engagement occurs downstream of microglial activation. To evaluate the functional consequences of inhibiting RIPK3, cognitive performance was tested using the MWM. As expected, and similarly to the result described above, mice subjected to Aβo infusion underwent significant memory impairment. Remarkably, the results of the test revealed that treatment with GSK’872 provided significant protection against Aβo-induced memory loss, as mice challenged with Aβo and treated with the drug, behaved similarly to control animals (Fig. 4E, F). The time that mice spent in the target quadrant during the test is graphically represented in the heat map (Fig. 4G). The results shown in Fig. 4H, I suggest that Aβo treatment did not cause locomotor or visual damage in these mice. Noteworthy, a negative correlation between neurodegeneration assessed by Fluoro-Jade C and cognitive performance was observed in these mice (Fig. 4J).

Together, these findings suggest that neurodegeneration induced by Aβo is mediated by the necroptotic machinery and that targeting necroptosis provides significant neuroprotection and results in cognitive improvement in experimental AD.

**Neurodegeneration triggered by Aβo-stimulated microglia occurs through necroptosis activation**

As indicated above, AD brains are characterized by the presence of reactive microglial cells associated with Aβ aggregates [10–12, 14]. This can be observed in human AD as well as in murine AD models (see Fig. 1C). Moreover, a role for microglia as mediators of Aβ-induced neurodegeneration has been extensively demonstrated [9]. Interestingly, it has been reported that rather than fibrillar amyloid, soluble oligomeric Aβ structures can more effectively potentiate a proinflammatory microglial response leading to neurodegeneration [55–59]. We then sought to explore whether microglial activation triggered by Aβo can elicit activation of the necroptotic pathway in neurons. We used synthetic Aβo, and their cytotoxic properties were first assessed in primary neurons. Oligomers triggered progressive neurodegeneration, evidenced by beading and retraction of neuronal processes, that was extensive after 72 h of incubation (Additional file 7: Fig. S7A-C). Notably, the addition of microglial cells to neuronal cultures significantly enhanced Aβo neurotoxicity (Additional file 7: Fig. S7D, E).

To test the possible involvement of microglia-secreted factors to the induction of necroptosis-mediated neuronal death, hippocampal neurons were treated with conditioned medium from primary rat microglial cells stimulated with Aβo (CMAB, Fig. 5A). Treatment with CMAB induced broad neuronal degeneration and the neurotoxic effects were dose-dependent (Fig. 5B, C). We then performed western blot analyses to determine the activation of necroptosis by analyzing the levels of RIPK3 and pMLKL in neurons upon treatment with CMAB. Densitometric analysis showed increased levels of RIPK3 (Fig. 5D) and pMLKL (Fig. 5E) in neurons exposed to CMAB compared with neurons treated with CMctrl (full blots are shown in Additional file 8: Fig. S8A, B). The physical interaction between RIPK1, RIPK3, and MLKL within the necosome complex leads to MLKL phosphorylation, resulting in its oligomerization and execution of necroptosis [33]. In order to further determine if CMAB triggers the formation of the necosome in neurons, co-immunoprecipitation experiments were performed followed by western blot analysis. These results revealed a significantly higher RIPK1-pMLKL interaction in neurons treated with CMAB compared with neurons treated

(See figure on next page.)

**Fig. 3** MLKL ablation ameliorates neurodegeneration and memory loss induced by Aβo in mice. **A, B** Representative micrographs and quantitative analysis of brain sections from wild-type mice subjected to intracerebroventricular infusion of Aβo or vehicle at 18 days post-injection, immunostained with an Iba1 specific antibody (scale bar, 150 μm). **C, D** Representative images and quantitative analysis of brain sections immunolabeled with an anti-non-phosphorylated neurofilament antibody at 18 days post Aβo injection (scale bar, 150 μm). **E, F** Representative images and quantitative analysis of brain sections immunolabeled with an anti-pMLKL antibody at 18 days post Aβo injection (scale bar, 150 μm). Association analyses of **G** pMLKL and Fluoro-Jade C stained area and **H** pMLKL stained area and cognitive performance, were done by linear regression. **I, J** Representative micrographs and quantitative measurement of brain sections from mice, treated as indicated in the images at 18 days post Vehicle or Aβo injection, stained with Fluoro-Jade C (scale bar, 150 μm). n = 13 per group, 4 sections per brain, one image of the hippocampus per section was analyzed. **K, L, N, O** The graphs represent quantitative analyses of the indicated parameters, obtained from the MWM test. **M** The heat map shows a graphic representation of the time that mice, treated as indicated in the image, spent in the target quadrant (TQ) during the MWM test. Data are presented as mean ± S.E.M. The data in **B, D, and F** were analyzed by Student’s t-test. Data in **G and H** were analyzed by linear regression using Pearson correlation. Data in **J, L, N, and O** were analyzed by one-way ANOVA followed by Bonferroni post-test. *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 3  (See legend on previous page.)
with CMctrl, indicating that CM\textsuperscript{Aβ} was able to enhance the formation of the necrosome complex (Fig. 5F, full blots are shown in Additional file 8: Fig. S8C). Finally, to define the involvement of necroptosis in neuronal death in this setting, we treated cells with the RIPK1 antagonist nec-1 \textsuperscript{s} or with the RIPK3 inhibitor GSK'872, prior to the addition of CM\textsuperscript{Aβ} to the cultures. Importantly, neurons treated with CM\textsuperscript{Aβ} together with nec-1 \textsuperscript{s} or GSK'872 showed significant protection from neurodegeneration compared with neurons treated with CM\textsuperscript{Aβ} alone (Fig. 5G–J).
Together, these data suggest that in response to stimulation with Aβo, neurotoxic factors released by activated microglia drive the formation of the necrosome and the initiation of the necroptosis signaling cascade in neurons.

**TNF-α released by Aβo-stimulated microglia contributes to necroptosis activation**

The secretion of TNF-α by Aβo-stimulated microglial cells has been previously described [47]. It has been demonstrated that activation of TNFR1 by TNF-α can trigger cell death via activation of the necroptotic pathway [31, 60]. Hence, we next investigated the possible contribution of TNF-α to Aβo-induced necroptosis. To this end, CM<sub>Aβ</sub> was incubated with the anti-TNF-α antibody Infliximab to neutralize the protein and was then used to treat neuronal cultures. Remarkably, Infliximab provided significant protection to neurons compared to neurons treated with control CM<sub>ctrl</sub>, which showed a high proportion of neuritic beading (Fig. 5K, L). To test whether the neuroprotection provided by Infliximab was due to the inhibition of necroptosis activation, we monitored the levels of pMLKL. Western blot analysis of neurons treated with CM<sub>Aβ</sub> together with Infliximab showed decreased pMLKL levels compared to neurons treated with CM<sub>Aβ</sub> alone (Fig. 5M, N; full blots are shown in Additional file 8: Fig. S8D). To assess the sufficiency of TNF-α to trigger necroptosis-mediated neurodegeneration, we treated neuronal cultures with recombinant TNF-α. A concentration of 40 ng/ml was used, as it has been previously shown that when combined with apoptosis inhibitors, it is able to trigger necroptosis in vitro [61, 62]. As shown in Additional file 9: Fig. S9A, B, neither treatment with TNF-α alone nor in combination with CM<sub>ctrl</sub> induced neurodegeneration.

**Discussion**

Several studies have demonstrated the involvement of necroptosis in the pathogenesis of neurodegenerative diseases, including PD [41], MS [40], ALS [39], Huntington disease [63], and ischemic neuronal injury [64]. It has been recently shown that necroptosis is activated in human AD brains [26, 27]. However, the mechanism by which this pathway is activated in AD is currently unknown. Here, we define a role for Aβ pathology in necroptosis activation in AD and demonstrate that microglial cells mediate Aβo-induced necroptosis activation in neurons.

The abnormal deposition of Aβ results from an imbalance between its production and clearance, constituting a crucial and probably causative event in the development of AD [2]. Nevertheless, Aβ appears to interact with multiple receptors, different types of cells and affect many biological processes and still, the exact mechanism by which neurons die in AD is not clear. Our results demonstrate a spatial correlation between Aβ pathology and the necroptosis effector pMLKL in AD brains and a correlation between Aβ burden and the expression of key necroptosis drivers, suggesting a possible link between Aβ aggregation and the activation of the necroptosis signaling pathway. Whereas Aβ plaques have long been a signature of AD histopathology, increasing studies over the past decade have demonstrated that soluble oligomeric Aβ constitutes the most neurotoxic type of Aβ aggregate [3, 5, 65, 66]. Accordingly, Brody et al., hypothesized that plaques may serve as a reservoir for toxic oligomers,
Fig. 5  (See legend on previous page.)
thereby capturing them in the extracellular space. It was suggested that over time, plaques get saturated and therefore oligomers can diffuse and exert their toxicity to the surrounding cells [4]. In agreement with this hypothesis, Koffie and colleagues demonstrated that oligomeric Aβ associated with plaques colocalizes with postsynaptic densities and is associated with spine collapse and synapse loss in postmortem AD samples [7]. Consistent with this evidence, our data point to oligomeric Aβ as a driver of necroptosis activation in AD, leading to neurodegeneration and memory loss. Although a previous report found no correlation between Aβ and necroptosis markers in AD brains, in this study the researchers considered Aβ plaque load and not oligomers for the analysis [26].

Many studies have demonstrated that the aggregation process of Aβ follows a seeding-nucleation mechanism that involves the formation of multiple types of intermediates including oligomers and fibrils [67, 68]. Additional studies are necessary to test the role of insoluble fibrillar Aβ in the activation of necroptosis. In addition, previous studies have shown colocalization between pτau and necroptosis markers in AD brains [26, 27], which is not surprising considering the mounting evidence proving the synergistic contribution of both misfolded Aβ and tau proteins to neurodegeneration [61–64]. Further studies would be required in order to test a potential interplay between both proteins for necroptosis activation.

In agreement with the study by Caccamo et al. [26], our results suggest that inhibition of the necrotic pathway prevents neurodegeneration in AD. Previous data from our group provided evidence for a functional role of necroptosis in PD, as necroptosis inhibition improved motor performance in a PD model [41]. Importantly, the present study is the first to unveil the functional implications of targeting necroptosis in an experimental AD model. As necroptosis is a druggable pathogenic mechanism, our findings suggest that necroptosis inhibition has an important translational potential for AD.

Several pathological processes may trigger activation of the necrotopic cascade in AD, including inflammation and oxidative stress. Our data suggest that upon interaction with Aβo, microglial cells secrete cytotoxic molecules that induce neurodegeneration via necroptosis activation. Among the secretory mediators released by microglia, TNF-α elicits necroptosis in vitro and in vivo [31, 60]. Accordingly, previous studies in other neurodegenerative conditions, including MS and ALS, demonstrated that sustained inflammation is associated with TNF-α-mediated necroptosis [73, 74]. In line with this evidence, our work suggests that TNF-α released from microglial cells following its activation by Aβo contributes to necroptosis-mediated neurodegeneration. Aβ can stimulate signaling responses in microglial cells that induce the release of a number of molecules that can contribute to neurodegeneration. Interestingly, there is evidence showing that glutamate, which has been previously demonstrated to be released by activated microglia [75, 76], can also induce necroptosis activation [77, 78]. Similarly, interferon-γ, which is produced by reactive microglia [79], has also been shown to participate in the activation of the necrototic signaling pathway [29]. Additional studies are needed to unveil the microglial protein expression profile in response to Aβo stimulation and define the exact molecules involved in the activation of the necrototic pathway.

Overall, in the present study, we provide new insights into the mechanism by which necroptosis is activated in AD, adding a new layer of complexity involving the crosstalk between microglia and neurons. Our results may contribute to understanding the mechanisms that lead to neurodegeneration in AD and support the view of necroptosis as a potential therapeutic target for disease intervention.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40478-022-01332-9.

---

**Additional file 1:** Fig. S1. Validation of the pMLKL immunoreactivity by DAB staining. Representative micrographs of hippocampal brain areas of AD patients (n = 3) immunostained with anti-pMLKL antibody. Orange arrows indicate pMLKL-positive neurons, and green arrows show pMLKL-positive microglia. Magnification, 20X.

**Additional file 2:** Fig. S2. Coefficient of variation of the dot-blot assays. The coefficient of variation (CV) was calculated using triplicates of Braak V-VI samples. A CV of 11.63% and 15.06% was determined for OC and A11, respectively.

**Additional file 3:** Fig. S3. Validation of the pMLKL antibody and assessment of cell specificity. Representative micrographs of (A) the dentate gyrus (DG) and (B) CA1 brain regions from wild-type and MLKL knockout mice subjected to intracerebral injection of Aβo, immunostained with anti-pMLKL antibody (scale bar, DG: 100 μm, CA1: 150 μm). (C, D) Representative images of the hilus of wild-type mice treated with Aβo, labeled with the indicated antibodies (scale bar, 50 μm and 25 μm for magnifications).

**Additional file 4:** Fig. S4. Intracerebral administration of Aβo elicits neurodegeneration in wild-type mice. Representative micrographs of brain sections from wild-type mice treated as indicated in the images, stained with Fluoro-Jade C (scale bar, 150 μm).

**Additional file 5:** Fig. S5. MLKL inhibition attenuates Aβo-induced microgliosis in mice. (A, B) Representative micrographs and quantitative analysis of brain sections from wild-type and MLKl knockout mice treated as indicated in the images, immunostained with anti-Iba1 antibody (scale bar, 200 μm). The data are presented as mean ± S.E.M. and were analyzed by one-way ANOVA followed by Bonferroni post-test. *p < 0.05.

**Additional file 6:** Fig. S6. RIPK3 inhibition does not alter Aβo-induced microgliosis in wild-type mice. (A, B) Representative micrographs and quantitative analysis of brain sections from wild-type mice treated as indicated in the images, immunostained with anti-Iba1 antibody (scale bar, 200 μm). The data are presented as mean ± S.E.M. and were analyzed by one-way ANOVA followed by Bonferroni post-test. *p < 0.05; **p < 0.01.
Acknowledgements
We thank Dra. Claudia Duran for suggestions and Dr. Claudio Hetz for critical review of the manuscript.

Authors’ contributions
N.S. designed research; N.S., I.M.G., N.G., G.Q., L.V., S.J., and M.E. performed research; N.S., I.M.G. and J.V. analyzed data; C.S., A.G., I.M.G. and J.V. contributed new reagents or analytic tools; N.S. wrote the paper; F.C. supervised research and edited the paper. All authors read and approved the final manuscript.

Funding
This study was funded by grants from FONDECYT No. 3180341 (to NS); FONDECYT ECYT No. 1190518 and FONDAP program 15150501 (to FC); Cajal Research Program CIP2015-5858/AF (to IMG); ECYT No. 1190518 and FONDAP program 15150012 (to FC); Instituto de Salud Carlos III (I3i) (to AG); and the Ministry of Science and Innovation through grants PID2019-107090RA-I00 and Ramon y Cajal Program RYC-2017-22034 (to AG) and grants from NIH R01AG059321 and R01AG061069 (to CS).

Declarations
Competing interests
The authors report no competing interests in relation to this manuscript.

Author details
1 Center for Integrative Biology, Faculty of Sciences, Universidad Mayor, Santiago, Chile. 2 FONDAP Geroscience Center for Brain Health and Metabolic Diseases, Santiago, Chile. 3 Department of Cell Biology, Facultad de Ciencias, Universidad de Malaga, IRBMA, Malaga, Spain. 4 Networking Research Center on Neurodegenerative Diseases (CIBERNEDE), Madrid, Spain. 5 Mitchell Center for Alzheimer’s Disease, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. 6 Dpto. Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, 41012 Sevilla, Spain. 7 Institute of Biomedicina de Sevilla (IBIS)-Hospital Universitario Virgen del Rocío/CSC, Universidad de Sevilla, 41013 Sevilla, Spain. 8 Buck Institute for Research on Ageing, Novato, CA, USA. 9 Present Address: Laboratory of Neurodegenerative Diseases, Faculty of Sciences, Universidad Mayor, Temuco, Chile.

Received: 17 February 2022 Accepted: 18 February 2022
Published online: 09 March 2022

References
1. Alzheimer’s Association, 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 16, 391–460 (2020).
2. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608
3. Cline EN, Ricca MA, Viola KL, Klein WL (2018) The amyloid-β oligomer hypothesis. Beginning of the third decade. J Alzheimer’s Dis 64:5567–5610
4. Brody DL, Jiang H, Wildburger N, Espana T (2017) Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease. Alzheimer’s Res Therapy 9:1–13
5. Espana T et al (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73:104–119
6. Hong S et al (2014) Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82:308–319
7. Koffie RM et al (2009) Oligomeric amyloid-β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012–4017
8. Wang J, Gu BJ, Masters CL, Wang YJ (2017) A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain. Nat Rev Neuro 13:612–623
9. Heneka MT et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neuro 14:388–405
10. Keren-Shaul H et al (2017) A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169:1276-1290.e17
11. Simard AR, Soulet D, Gowing G, Julien JP, Rivet S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neurog 49:489–502
12. Mosher KL, Wyss-Coray T (2014) Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol 88:594–604
13. Lee S et al (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am J Pathol 177:2549–2562
14. McGeer PL, Itagaki S, Tago H, McGeer EG (1988) Occurrence of HLA-DR antigens on microglial cells in Alzheimer’s disease. Ann N Y Acad Sci 510:324–328
15. Combs CK, Karlo JC, Kao SC, Landreth GE (2001) Beta-amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci Off J Soc Neurosci 21:1179–1188
16. El Khoury JB et al (2003) CD36 mediates the innate host response to β-amyloid. J Exp Med 197:1657–1666
17. Miao J (2005) Reducing cerebral microvascular amyloid- protein deposition diminishes regional neuronal inflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci 25:6271–6277
18. Patel NS et al (2005) Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer’s disease. J Neuroinflammation 2:9
19. Fan R et al (2007) Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloidosis. J Neurosci Off J Soc Neurosci 27:3057–3063
20. R. Guerreiro, et al., TREM-2 variants in AD. 368, 117–127 (2013).
21. Jonsson T et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116
22. Takehoshi K, Reddy CDP, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647–657
23. Ma J, Jiang T, Tan L, Yu JT (2015) TYROBP in Alzheimer's disease. Mol Neurobiol 51:820–826
24. Wang Y et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160:1061–1071
25. Salvador N, Court FA (2020) The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade? Expert Opin Ther Targets 24:679–693
26. Caccamo A et al (2017) Necroptosis activation in Alzheimer's disease. Nat Neurosci. https://doi.org/10.1038/nn.4608
27. Kopper MJ et al (2019) Necrosmic complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-019-02103-y
28. Wang H et al (2017) PELI1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP. In: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.1715742114
29. Thapa RJ et al (2013) Interferon-induced RIP1/RIP3-mediated necrosis occurs IP3R and is licensed by FADD and caspases. Proc Natl Acad Sci 110:E3109–E3118
30. Kaiser WJ et al (2013) Toll‑like receptor 3‑mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 288:31268–31279
31. Remijien Q et al (2014) Depletion of RIP3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis 5:e1004
32. Kearney CJ et al (2015) Necroptosis suppresses inflammation via termination of TNF- or c-FLIP-induced cytokine and chemokine production. Cell Death Differ 22:1313–1327
33. Grootjans S, Berghe TV, Vandenabeele P (2017) Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ 24:1184–1195
34. Degterev A et al (2008) Identification of RIP1 kinase as a specific cellular target of necrostatin. Nat Chem Biol 4:313–321
35. He S et al (2009) Receptor interacting protein kinase‑3 determines cellular necrotic response to TNF‑α. Cell 137:1110–1111
36. Cho YS et al (2009) Phosphorylation‑driven assembly of the RIP1‑RIP3 complex regulates programmed necrosis and virus‑induced inflammation. Cell 137:1112–1123
37. Cai Z et al (2013) Plasmablast translocation of trimethylated MLKL protein is required for TNF‑induced necroptosis. Nat Cell Biol 16:55–65
38. Wallach D, Kang T-B, Dillon CP, Green DR (2016) Programmed necrosis in cancer. Nat Rev Cancer 16:1077–1092
39. Cai Z et al (2013) Plasma membrane translocation of trimerized MLKL protein in an Alzheimer's disease model. Cell 160:1061–1071
40. Ofengeim D et al (2015) Activation of necroptosis in multiple sclerosis. Cell Rep 10:1836–1849
41. Ohtake M et al (2019) The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ. https://doi.org/10.1038/s41418-019-0408-4
42. Wu J et al (2013) Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell 153:2944–3006
43. Kim HY, Lee DK, Chung BR, Kim HV, Kim Y (2016) Intracerebroventricular injection of amyloid-β peptides in normal mice to acutely induce Alzheimer-like cognitive deficits. J Vis Exp 20161:1–6
44. Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848–858
45. Sadilek KR et al (2016) Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease. Acta Neuropathologica 21:1–22
46. Jimenez S et al (2014) Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains. PLoS ONE 9:1–17
47. Floden AM (2015) Amyloid‑β‑induced deficits in an Alzheimer’s disease mouse model. Science 346:750–754
48. Salvador N, Court FA (2020) The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade? Expert Opin Ther Targets 24:679–693
49. Petersen RC et al (2009) Mild cognitive impairment: Ten years later. Arch Neurol 66:1447–1455
50. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspect Med 1:1102
51. Lu J et al (2019) Melatonin suppresses microglial necroptosis by regulating deubiquitinating enzyme A20 after intracerebral hemorrhage. Front Immunol 10:1–16
52. Huang Z et al (2018) Necroptosis in microglia contributes to neuroinflammation and retinal degeneration through TLR4 activation. Cell Death Differ 25:180–189
53. Faucher P, Mons N, Miehe J, Louis C, Beracochea DJ (2016) Hippocampal injections of injective selective working memory deficits and long-lasting alterations of ERK. Signaling Pathway 7:1–15
54. Wang G et al (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase‑4‑related signaling. Oncotarget 7:17380–17392
55. Paranjape GS, Gouwens UK, Ostborn DC, Nicholls MR (2012) Isolated amyloid-β(1–42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. ACS Chem Neurosci 3:238–247
56. Xu H et al (2016) Environmental enrichment potently prevents microglia-mediated neuroinflammation by human amyloid β-protein oligomers. J Neurosci 36:9041–9056
57. Ludtbøtte A et al (2020) Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem 155:650–661
58. Sondag CM, Dhawan G, Combs CK (2009) Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6:1–13
59. Dhawan G, Floden AM, Combs CK (2012) Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging 33:2247–2261
60. Liu S et al (2014) Necroptosis mediates TNF‑induced toxicity of hippocampal neurons. BioMed Res Int 20:14
61. He S et al (2009) Receptor interacting protein kinase‑3 determines cellular necrotic response to TNF‑α. Cell 137:1100–1111
62. Hou J et al (2019) Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis 10:4943
63. Zhu S, Zhang Y, Bai G, Li H (2011) Necrostatin‑1 ameliorates symptoms in an Alzheimer’s disease model. Neurobiol Aging 32:1072–1086
64. Degterev A et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1:112–119
65. Viola KL, Klein WL (2015) Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129:183–206
66. Lacro PN et al (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 27:796–807
67. Caughey B, Lansbury PT (2003) Proteofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:277–298
68. Soto C, Estrada L, Castilla J (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31:150–155
69. Bloom GS (2014) Amyloid-β and tau: the trigger and bulb in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508
70. Nishiocha C, Liang HF, Barsamian B, Sun SW (2019) Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model. Neuroimmunology 189:180–191
71. Roberson ED et al (2007) Reducing endogenous tau ameliorates amyloid-β-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754
72. Salvador N, Gerónimo-Olvera C, Court FA (2020) Axonal degeneration in AD: the contribution of Aβ and Tau. Front Aging Neurosci 12:1–16
73. Yuan J, Amin P, Ofengeim D (2019) Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci 20:19–33
74. Wegener KW, Saleh D, Degterev A (2017) Complex pathologic roles of RIPK1 and RIPK3: moving beyond necroptosis. Trends Pharmacol Sci 38:202–225
75. Noda M, Nakanishi H, Akaike N (1999) Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 92:1465–1474
76. Klegeris A, Walker DG, McGeer PL (1997) Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol 78:152–161
77. Xu X et al (2010) The role of PARP activation in glutamate-induced necroptosis in HT-22 cells. Brain Res 1343:206–212
78. Hernández DE et al (2018) Axonal degeneration induced by glutamate excitotoxicity is mediated by necroptosis. J Cell Sci 131:jcs214684
79. Kawanokuchi J et al (2006) Production of interferon-gamma by microglia. Multiple Sclerosis (Houndmills, Basingstoke, England) 12:558–564

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.